Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

BACKGROUND: Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood–brain barrier (BBB) penetration is highly desirable. METHODS: The design and structure–activity relatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, McAndrew, Nicholas P., Wang, Xiaojia, Du, Yiqun, DiCarlo, Brian, Wang, Mei, Chen, Kan, Yu, Wenlei, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327353/
https://www.ncbi.nlm.nih.gov/pubmed/37415239
http://dx.doi.org/10.1186/s13058-023-01679-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327353/
https://www.ncbi.nlm.nih.gov/pubmed/37415239
http://dx.doi.org/10.1186/s13058-023-01679-4

Ejemplares similares